BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
BIOCRYST PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $625.85M | $630.77M | $623.15M | $593.30M | $551.63M | $497.18M | $442.67M | $404.06M | $373.29M | $345.80M | $324.70M | $312.02M | 66.5% | +13.5% |
| ORLADEYO | $617.31M | $615.94M | $601.84M | $574.34M | $531.59M | $483.04M | $437.66M | $404.36M | $373.72M | $346.44M | $325.99M | $305.84M | 65.6% | +16.1% |
| Collaborative and other revenues | – | $7.96M | $7.71M | $6.52M | $5.88M | $6.30M | $8.04M | $8.52M | $8.95M | $9.59M | $6.72M | $5.54M | – | – |
| Other revenues | – | $22.78M | $29.02M | $25.47M | $25.92M | $20.45M | $13.05M | $8.22M | $8.51M | $8.95M | $5.42M | $11.71M | – | – |
By region
From the segment and revenue-disaggregation notes of Biocryst Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.